Novavax COVID-19 vaccine: no new safety concerns

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1971卷 / 1期

关键词：

D O I：

10.1007/s40278-023-45135-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：10 / 10

相关论文

共 50 条

[1] FDA Authorizes Novavax COVID-19 Vaccine
Abramowitz, Mark
Pflomm, Jean-Marie
Damn, Susan M.
Faucard, Amy
Morrison, Corinne Z.
Viscusi, Michael P.
Esterow, Joanna
Sacks, Mordechai
Shah, Brinda M.
Swanson, F. Peter
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2022, 64 (1656): : 121 - +
[2] Covid-19: Whatever happened to the Novavax vaccine?
Tinari, Serena
Riva, Catherine
BMJ-BRITISH MEDICAL JOURNAL, 2021, 375
[3] Novavax COVID-19 Vaccine Booster Authorized
Larkin, Howard D.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (21): : 2101 - 2101
[4] COVID-19 vaccine in adolescents: no new serious safety concerns identified
Reactions Weekly, 2023, 1955 (1) : 10 - 10
[5] Safety update on COVID-19 vaccine Comirnaty finds no new concerns
Reactions Weekly, 2021, 1842 (1) : 3 - 3
[6] FDA approves updated Novavax COVID-19 vaccine
不详
NURSE PRACTITIONER, 2023, 48 (12): : 48 - 48
[7] Novavax COVID-19 vaccine-related myocarditis/pericarditis
Reactions Weekly, 2023, 1946 (1) : 12 - 12
[8] Novavax COVID-19 vaccine-related myocarditis, pericarditis
Reactions Weekly, 2022, 1921 (1) : 4 - 4
[9] Novavax COVID-19 vaccine-related myocarditis and pericarditis
Reactions Weekly, 2022, 1925 (1) : 3 - 3
[10] CEPI commits $384 million to Novavax's COVID-19 vaccine
Cross, Ryan
CHEMICAL & ENGINEERING NEWS, 2020, 98 (20) : 11 - 11

← 1 2 3 4 5 →